Reports of a patient with KRAS mutant renal cell carcinoma showed a dramatic response to trametinib (MEK inhibitor) initially, and was found to have Met over-expression upon relapse, which was sensitive to treatment with crizotinib, an ALK and Met inhibitor 55. The gene discussed is MAP2K7; the disease is renal cell carcinoma.